Frederik Deroose. Ph.D.
Vice President, Business Development and Director Medicinal Chemistry
Frederik Deroose, Vice President, Business Development and Director Medicinal Chemistry, has more than 25 years of experience in drug research and is part the drug discovery team at Linnaeus. Dr. Deroose manages medicinal chemistry programs at Linnaeus, by designing novel, therapeutically relevant compounds. He maintains oversight of all compound related data, including analytical, synthesis and biological data, and develops Structure Activity Relationships (SAR) and Structure Property Relationships (SPR) related to the ongoing drug discovery programs. He is designing novel molecules and coordinating Design-Make-Test cycles in Lead Optimization efforts. He is directly working with the synthetic chemists responsible for executing chemistry plans and is working closely with the Linnaeus Team in order to coordinate the testing of the compounds (including biology, ADME, in vivo efficacy, etc.). Frederik has in depth expertise in the coordination of drug discovery programs. Before joining Linnaeus in 2014, Frederik was Director at Janssen Pharmaceuticals (part of Johnson and Johnson) in the medicinal chemistry team for 18 years where he was a key contributor in numerous discovery programs and an inventor of multiple New Molecular Entities (NMEs) in the fields of Inflammation, Neuroscience and Oncology and Anti-Infectives. Frederik has experience in anti-infective discovery programs and is currently an active member of the IMI-funded consortium ENABLE (European Gram Negative Antibacterial Engine) as part of the ‘New Drugs for Bad Bugs’ (ND4BB) program. The ENABLE project is working to advance the development of potential antibiotics against Gram-negative bacteria. He received his Ph.D. in Organic Chemistry, 1995 from University Ghent, Belgium and performed postdoctoral research at the Scripps Research Institute, San Diego on Natural product and medicinal chemistry.